POTENTIAL THERAPEUTIC USE OF A BIOACTIVE COMPOUND WITH IMMUNE PROPERTIES Bioactive compounds
Main Article Content
Keywords
bioactive compounds, Clinical Pharmacology and Therapeutics, Dental extraction, Oral surgery, Patient satisfaction, student competence
Abstract
Oral and mouth cancers are the most prevalent among head and neck cancers. Typically, people over the age of 60 are affected. Besides your lips, your tongue, and your ceiling are some places you can develop oral cancer. Additionally, it impacts your oropharynx, including the roof of your mouth, tonsils, and the sides and back of your throat. Oral carcinoma is a serious health problem that is treated with hormones, surgery, chemotherapy, and radiation therapy. Nearly every year, more than 450,000 new cases of oral cancer are discovered, and 40 to 50 percent of these patients have a survival rate of fewer than five years. In addition to smoking and chewing tobacco, alcohol abuse, HPV infection, and betel nut consumption are major risk factors for oral cancer. Although radiation and chemotherapy play an essential function, their effectiveness is sometimes limited. The location, stage, and general health of the patient are considered when choosing a treatment. However, there is now more focus on natural products, particularly those from marine sources, due to cancer cells' resistance to synthetic drugs and secondary cancer formation. Therapeutic researchers evaluate several diagnostic and prognostic biomarkers of head and neck squamous cell carcinoma, but their clinical relevance is still debatable.
References
[2] Pradhan B, Patra S, Behera C, Nayak R, Patil S, Bhutia SK, et al. Enteromorpha compressa extract induces anticancer activity through apoptosis and autophagy in oral cancer. Molecular Biology Reports. 2020;47:9567-78.
[3] Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. 1995.
[4] Cheng M-F, Lin C-S, Chen Y-H, Sung P-J, Lin S-R, Tong Y-W, et al. Inhibitory growth of oral squamous cell carcinoma cancer via bacterial prodigiosin. Marine drugs. 2017;15:224.
[5] Alexandrova EM, Yallowitz A, Li D, Xu S, Schulz R, Proia D, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015;523:352-6.
[6] Hong B, Prabhu VV, Zhang S, van den Heuvel APJ, Dicker DT, Kopelovich L, et al. Prodigiosin Rescues Deficient p53 Signaling and Antitumor Effects via Upregulating p73 and Disrupting Its Interaction with Mutant p53Rescuing Deficient p53 via p73 in Cancers. Cancer research. 2014;74:1153-65.
[7] Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochemical pharmacology. 2005;69:407-14.
[8] Han Y, Cui Z, Li Y-H, Hsu W-H, Lee B-H. In vitro and in vivo anticancer activity of pardaxin against proliferation and growth of oral squamous cell carcinoma. Marine Drugs. 2015;14:2.
[9] Meek DW. Regulation of the p53 response and its relationship to cancer. Biochemical Journal. 2015;469:325-46.
[10] Pace E, Siena L, Ferraro M, Profita M, Mondello P, Chiappara G, et al. Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. European Journal of Cancer. 2006;42:2382-9.
[11] Lin C-W, Bai L-Y, Su J-H, Chiu C-F, Lin W-Y, Huang W-T, et al. Ilimaquinone induces apoptosis and autophagy in human oral squamous cell carcinoma cells. Biomedicines. 2020;8:296.
[12] Yeh C-C, Yang J-I, Lee J-C, Tseng C-N, Chan Y-C, Hseu Y-C, et al. Anti-proliferative effect of methanolic extract of Gracilaria tenuistipitata on oral cancer cells involves apoptosis, DNA damage, and oxidative stress. BMC Complementary and Alternative Medicine. 2012;12:1-9.
[13] Sivaperumal P, Sekaran S, Kamala K, Ganapathy D. Marine bioactive compounds as potential therapeutic inhibitor for oral squamous cell carcinoma (OSCC). Oral oncology. 2022;131:105971.
[14] Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Frontiers in immunology. 2019;10:1205.
[15] Kumaresan V, Sivaperumal P, Girija AS. Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells-Multifunctional therapeutic approach against oral cancer. Oral oncology. 2022;132:106013.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Santhoshkumar Jayakodi
Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai 602105, TN, India,